YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced its financial results for the year and quarter ending December 31, 2024, spotlighting strong growth in XHANCE prescriptions and revenue. The company also marked a significant milestone by reporting income from operations for the first time.
Net revenue from XHANCE, Optinose’s flagship product for managing chronic rhinosinusitis with nasal polyps, reached $22.4 million in the fourth quarter, a 13% increase from $19.9 million in the same period last year. For the full year, XHANCE net revenue grew 10%, totaling $78.2 million compared to $71.0 million in 2023. The company attributed this solid performance to a rise in both new prescriptions (NRx) and total prescriptions (TRx).
Prescription demand saw a notable boost during the fourth quarter, with NRx climbing 12% from approximately 25,600 in the third quarter to 28,700. TRx jumped 23%, increasing from around 63,900 to 78,500 during the same period. These results underscore the growing adoption of XHANCE among healthcare providers and patients.
Operating expenses for 2024 included $3.9 million in research and development costs as the company continues to focus on expanding its pipeline. Selling, general, and administrative expenses totaled $83.5 million for the year, contributing to a slight year-over-year increase in total expenses.
Optinose achieved a key financial milestone during the fourth quarter by reporting $0.4 million in income from operations for the first time in the company’s history. This achievement reflects disciplined cost management alongside sustained revenue growth.
Despite the progress, the company reported a net loss of $0.4 million for the three-month period, or $0.04 per share, and $21.5 million for the full year, or $2.12 per share.
The 2024 financial results position Optinose for a strong trajectory, with continued momentum in prescription growth and revenue generation. The company’s ability to achieve operational income signals significant strides toward financial sustainability while reinforcing its commitment to delivering effective treatment options for patients.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.